BioCardia announces first patient enrolled at Henry Ford Health in Phase 3 CardiAMP HF II trial

BioCardia, Inc.

First patient enrolled at Henry Ford Health in Phase 3 CardiAMP HF II trial for ischemic heart failure with reduced ejection fraction.
Prior CardiAMP HF study showed reduced mortality and major adverse cardiac events in patients with elevated NTproBNP.
Phase 3 is a 250-patient randomized, placebo-controlled confirmatory study using a three-tier composite primary endpoint.
Primary endpoint composite: all-cause death, nonfatal MACE, and validated quality of life measure.
CEO notes ~2 million US and EU patients with NYHA Class II/III symptoms who may benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.